A new chapter is beginning for iPSCs: Qihan Biotech, a leading innovator in cell engineering, has reported the first clinical use of an induced pluripotent stem cell (iPSC)-derived CAR natural killer (NK) therapy in an autoimmune disease. The product, known as QN-139b, was administered to a patient with refractory systemic sclerosis (SSc), marking the first time an iPSC-derived CAR immune therapy has been used beyond oncology. [Read more…]
What Laboratories Must Do To Safeguard Digital Stem Cell Records
Preserving the integrity and confidentiality of digital records related to stem cell research is paramount for laboratories worldwide. Stem cells hold tremendous potential for regenerative medicine and therapy, leading to groundbreaking advancements. [Read more…]
Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF
SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA.
Exosomes, as a next-generation bioactive carrier, boast unique advantages such as low immunogenicity, strong tissue penetration, and potential for targeted modification, offering immense promise for medical applications. However, the technical barriers and research challenges in Exosome development place them at the forefront of complexity among bioactive material fields. [Read more…]
HeartBeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies
HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders
Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases. [Read more…]
The Pros and Cons of Stem Cell Research in 2026
Interested to understand the importance of stem cell research and recent advancements within this field of study? Today, there are approximately  250 companies worldwide that are developing stem cell products for therapeutic use in humans to address a diverse range of chronic and acute conditions. There are also around astounding 500,000+ scientific publications about stem cells that have been published today in peer-reviewed journals.
In this article, we’ll explore the pros and cons of stem cell research. Let’s dive in.
In this article:
- « Previous Page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- …
- 338
- Next Page »